Your session is about to expire
← Back to Search
Provider Communication for Cancer Risk Gene Testing
N/A
Recruiting
Led By Stacy W Gray
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 9 months after enrollment
Awards & highlights
Study Summary
This trial tests if provider-mediated communication of cancer risk gene test results can help increase genetic testing and counseling rates in families with cancer.
Who is the study for?
This trial is for English-speaking adults in the U.S. who have a known harmful gene change linked to cancer, seen by COH Genetics, and are willing to share contact info of their relatives. Relatives must also be adults in the U.S., fluent in English, and not previously tested for this genetic variant.Check my eligibility
What is being tested?
The study examines if healthcare providers can help increase genetic counseling and testing rates among at-risk family members by directly communicating genetic test results instead of relying on patients to pass along this information.See study design
What are the potential side effects?
Since this trial involves communication methods like personal contact and surveys rather than medical treatments, there are no direct physical side effects. However, learning about potential genetic risks could cause emotional or psychological stress.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 9 months after enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 9 months after enrollment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The percentage of uptake of cascade testing among patients' first-degree at-risk relatives
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm II (provider-mediated contact)Experimental Treatment3 Interventions
Patients receive a family letter and their genomic test report to share with at-risk first degree relatives and relatives also receive provider-mediated contact to discuss genetic results on study.
Group II: Arm I (usual care)Active Control3 Interventions
Patients receive a family letter and their genomic test report to share with at-risk first degree relatives on study.
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,665 Previous Clinical Trials
40,925,614 Total Patients Enrolled
1 Trials studying Blood Cancers
70 Patients Enrolled for Blood Cancers
City of Hope Medical CenterLead Sponsor
565 Previous Clinical Trials
1,921,220 Total Patients Enrolled
Stacy W GrayPrincipal InvestigatorCity of Hope Medical Center
2 Previous Clinical Trials
665 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have less than 2 close family members in the US eligible for genetic testing.I am a direct relative (parent, sibling, or child) of the person with the condition.I am unwilling to share my family's contact information.My close family members have not been tested for our known genetic condition.My immediate family members are all adults.My close family members have been tested for our known genetic condition.My close family member is part of this study and I have agreed to join as well.I have a genetic mutation linked to my condition.I am unable to understand or sign the consent form.I am enrolled in COH IRB 07047 or have been tested by COH Genetics.I am 18 years old or older.I have at least 2 close family members in the US who can be tested for genetics.
Research Study Groups:
This trial has the following groups:- Group 1: Arm I (usual care)
- Group 2: Arm II (provider-mediated contact)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there still vacancies available to participate in this trial?
"Affirmative. The clinicaltrials.gov listing indicates that recruitment for this medical trial is underway, having been initially posted on February 14th 2023 and most recently updated March 6th 2023. 240 subjects are sought from a single site."
Answered by AI
How many participants are currently being enrolled in this research endeavor?
"Agreed. Data hosted on clinicaltrials.gov affirms that this medical experiment, which was first published on February 14th 2023, is actively recruiting patients. Approximately 240 participants need to be recruiter from 1 different healthcare facility."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger